Frontier Biotechnologies Inc. is a research based, commercial-stage biopharmaceutical company with full capabilities in China currently, founded in 2002. We Discovered, developed and launched the first novel AIDS drug in China – Albuvirtide (ABT) (NDA approved by CFDA in 2018). We also have two late-stage product candidates:
1) All-injectable long-acting novel drug regimen – ABT + 3BNC117, a Ph2b clinical trial ongoing in US, 2nd Ph2b clinical trial for functional cure about to start in China
2) Third generation topical patch for pain management – AB001, a Ph2b clinical trial successfully completed in US
We would like to seek for licensing partnership in other emerging markets for the long-acting anti-HIV injection, Albuvirtide with whom has rich experience and solid government resources in this area.
If there’s anyone interested in this topic, pls contact me via below email address or cellphone:
crystalhao@frontierbiotech.com
+86 13910505049
Crystal Hao
Global BD Head of Frontier Biotechnologies Inc.